

Amendment under 37 CFR 1.111  
Hideshi FUJIWAKE  
June 11, 2003

Appln. Ser. No. 10/015,662  
Attorney Docket No. 011658  
Page 4

**IN THE CLAIMS:**

**Please amend claims 3, 5 and 6 as follows:**

---

1. **(Original)** An amino acid sequence determination for protein or peptide including the following steps (A) and (B):

(A) chemically cutting constitutive amino acid one by one from an N end of protein or peptide for liberating the constitutive amino acid; and  
(B) identifying the liberated constitutive amino acid by immunoassay utilizing an antibody against a derivative of the constitutive amino acid liberated by the chemical cutting.

2. **(Original)** The amino acid sequence determination according to claim 1, wherein the constitutive amino acid includes constitutive modified amino acid.

3. **(Presently Amended)** The amino acid sequence determination according to claim 1, wherein

the steps (A) and (B) are successively repeated one by one for every the constitutive amino acid.

4. **(Original)** The amino acid sequence determination according to claim 1, wherein the immunoassay is a competitive method.

**5. (Presently Amended)** The amino acid sequence determination according to claim 4,  
wherein

the immunoassay employs such a microplate that monoclonal antibodies for various types  
of PTH amino acids are fixed to respective wells of the microplate one by one and analogs analogues  
with labels to PTH amino acid derivative bonding with the respective monoclonal antibodies are  
previously added to be bonded with the monoclonal antibodies and includes steps of

- (1) dripping a solution containing PTH amino acid derivatives obtained by Edman  
degradation on to the microplate,
- (2) washing out non-bonded PTH amino acid derivative and analogs analogues liberated by  
competitive reaction,
- (3) adding labeled antibodies against analogs analogues, and
- (4) measuring the quantity of the labeled antibodies bonded with the analogs analogues.

*(13)*  
**6. (Presently Amended)** The amino acid sequence determination according to claim  
5, wherein

the quantity of the monoclonal antibodies in the respective wells as well as the quantity of  
the analogs analogues are fixed.